DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 27, 2005--Elan Corporation, plc today announced its third quarter 2005 financial results. Commenting on Elan's business, Kelly Martin, Elan's president and chief executive officer, said, "Our disciplined execution continued in the third quarter. On Tysabri, we completed the patient safety evaluation in both MS and CD/RA. In addition, for MS we submitted an sBLA to the FDA and a similar data package to the EMEA and we look forward to working with the regulatory agencies during the review process. In Alzheimer's, we advanced our immunotherapeutic approach. Our humanized monoclonal antibody program continues to progress and is currently in Phase II. Our second program, an active immunization conjugate, has entered Phase I clinical trials this quarter. These accomplishments, along with progress in our core businesses, continue to reinforce our commitment to moving toward profitability and building shareholder value. We remain dedicated to meeting unmet medical needs of patients. This continues to define us as a company and as individuals."
